Engene appoints ryan daws as chief financial officer

Boston and montreal , nov. 29, 2023 /prnewswire/ - engene holdings inc. ("engene,") (nasdaq: engn) (nasdaq: engnw), a clinical-stage genetic medicines company whose lead program is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced the appointment of ryan daws as chief financial officer and head of business development. "i am delighted to welcome ryan to engene at a critical time in our growth, as we move forward as a public company and work to advance our ongoing pivotal-stage eg-70 clinical study in bcg-unresponsive non-muscle invasive bladder cancer (nmibc)," said jason d.
ENGN Ratings Summary
ENGN Quant Ranking